About Glaukos
Glaukos is a publicly listed company based in Laguna Hills (United States) founded in 2001. Developer of implants to treat glaucoma. Glaukos has raised $117.57 million across 10 funding rounds from investors including Orbimed, Frazier Healthcare Partners and Meritech Capital. The company has 995 employees. Glaukos has completed 1 acquisition, including Avedro. Its website glaukos.com draws about 27 thousand monthly visits. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its competitors include Ivantis, Myra Vision and Transcend Medical; 3 of its 3 listed competitors have raised funding.
Company details
The company was founded in 2001 and is headquartered in Laguna Hills, United States, within the medical devices sector focused on ophthalmology. Operations center on the development of the Micro-Invasive Glaucoma Surgery (MIGS) method, including the iStent device, which is implanted during cataract surgery to reduce intraocular pressure. Additional platforms for bioerodible drug delivery targeting retinal disorders are also being advanced.
- Headquarters Laguna Hills, United States
- Employees 995
- Stage Public
- SectorsHealthcare
- Website glaukos.com
- Social LinkedIn X Facebook Instagram
- Legal Name Glaukos Corporation
- Annual Revenue$507.44 M (USD)32.33as on Dec 31, 2025
- Net Profit-$187.69 M (USD)-28.23as on Dec 31, 2025
- EBITDA-$44.39 M (USD)34.93as on Dec 31, 2025
- Total Equity Funding$117.57M (USD)
in 10 rounds
- Latest Funding Round$250M (USD), Post-IPO
Jun 2020
- InvestorsOrbimed
& 7 more
- Employee Count995
- Investments & Acquisitions
Funding Insights of Glaukos
Glaukos has successfully raised a total of $117.57M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $250 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $117.57M
- Total Rounds 10
- Last Round Post-IPO — $250M
- First Round $10M
(Sep 2002)
- Investors Count 8
All 10 funding rounds of Glaukos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $250M | Post-IPO | – | – | – |
| Jan 2013 | $30M | Series E | – | Meritech | |
| Oct 2012 | $6M | Series E | – | – | – |
| Aug 2012 | $4.5M | Debt – Conventional | – | – | – |
| Feb 2011 | $29.5M | Series E | – | Meritech | |
| Sep 2010 | $6M | Series D | – | – | – |
| Mar 2010 | $74,492 | Series D | – | – | – |
| Aug 2008 | $35M | Series D | – | – | |
| Jun 2006 | $1M | Series A | – | – | – |
| Sep 2002 | $10M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in Glaukos
Glaukos has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Frazier Healthcare Partners and Meritech Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward US-based companies. | meritechcapital.com | Palo Alto, United States | ||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Growth capital investments are made in healthcare and fintech companies. | mepvc.com | San Francisco, United States | ||
| fjordventures.com |
Investor details for Glaukos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Glaukos
247 people are tracked at Glaukos (72 in leadership, 6 in board & advisors, 169 in team); the tracked headcount is 995.
| Name | Role | Group |
|---|---|---|
Thomas W. Burns | President & CEO | Leadership |
Jay L. Katz | Chief Medical Officer | Leadership |
Brian Carr | Director, Market Access & Reimbursement | Leadership |
Cristina Sanchez Gonzalez | Marketing Director Europe, Middle East, India | Leadership |
Richard Norman | Director Medical Affairs & Training (emeai) | Leadership |
David Usher | Senior Director Software And Applied Research | Leadership |
Joseph E. Gilliam | President & COO | Leadership |
Jennifer Seal | Sr. Director Pharmacokinetics, Drug Disposition, And Clinical Pharmacology | Leadership |
Meredith K. | Director Of Compliance | Leadership |
Tomas Navratil | Chief Development Officer | Leadership |
Siva Nagireddy | Director Of Quality Assurance | Leadership |
Emily Kelly | Area Director, Southeast | Leadership |
Sharal Pellegrini | Sr. Director, Clinical Research Operations | Leadership |
Shrina Punjabi | Director, Clinical Compliance | Leadership |
Alex R. Thurman | VP, Finance | Leadership |
Cody McKenzie | Vice President, Global Marketing | Leadership |
Jane Ellen Giamporcaro | Senior Director, Global Clinical Research, Science, & Strategy | Leadership |
Jason Hill | Director of Drug Development | Leadership |
Kenneth Curry | Vice President, Appplied Research | Leadership |
Dari Parizadeh Pharm.d. | Sr. Director, Clinical Research | Leadership |
227 more people are available in the full profile.
Complete people profiles for Glaukos
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Glaukos
Glaukos is a publicly listed company on the NYSE with ticker symbol GKOS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Jun 2015
- Listed onNYSE: GKOS
- Listed entityGlaukos Corporation
- Exchange sectorHealth technology
- ISINUS3773221029
- Share price$165.50 (-1.5% on the day) · 2026-10-13
- Market capitalisation$9.76B
- EPS (diluted, trailing year)$-3.26
- Volume (last session)909,898
Financials of Glaukos
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $507.4M | -$187.7M | -$44.4M |
| 2024 | $383.5M | -$146.4M | -$68.2M |
| 2023 | $314.7M | -$134.7M | -$85.7M |
| 2022 | $282.9M | -$99.2M | -$66.4M |
| 2021 | $294.0M | -$49.6M | -$18.4M |
Detailed financial statements for Glaukos
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Glaukos
Glaukos has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Avedro.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Corneal collagen cross-linking technology is developed for ophthalmic applications. | avedro.com | Waltham, United States | 2007 | Aug 2019 | •••• |
Complete acquisition details for Glaukos
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Glaukos
5 dated milestones of Glaukos across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Glaukos is founded.
- Funding First funding round of $10.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Avedro.
- Funding Latest funding round, Post-IPO, of $250.0M.
Competitors of Glaukos
Glaukos has 3 listed competitors in our database, 3 of them funded. They include Ivantis, Myra Vision and Transcend Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ivantisinc.com | 2007 | Irvine, United States | $166.23M | 132 | Implantable device to relieve intraocular pressure in open angle glaucoma | |
| myravision.com | 2019 | Campbell, United States | $42M | Nanotechnology-based devices for glaucoma treatment are developed. | ||
| transcendmedical.com | 2006 | Menlo Park, United States | $122.27M | 20 | Minimally invasive glaucoma stents are developed to enhance aqueous outflow. |
Detailed competitors of Glaukos
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Glaukos
The website of Glaukos (glaukos.com) receives about 26.6K visits a month.
- Monthly visits26.6K
▼ 8.9% vs previous month
Websites whose visitors overlap most with Glaukos. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
glaucomaexpert.com | glaucomaexpert.com | 100% | – | ||
oftalica.com | oftalica.com | 100% | #1,404,707 | – | |
healio.com | healio.com | 95% | #72,463 | – | |
glaucomatoday.com | glaucomatoday.com | 83% | #531,663 | – | |
eyetube.net | eyetube.net | 77% | #472,870 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Glaukos
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Glaukos (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Glaukos
Complete news archive for Glaukos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glaukos
Glaukos was founded in 2001 and raised its 1st funding round 1 year after it was founded.
Glaukos is headquartered in Laguna Hills, United States. It is registered at Laguna Hills, California, United States.
Glaukos is a funded company, having raised a total of $117.57M across 10 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Sep 2002.
Glaukos has 995 employees.
Annual revenue of Glaukos is $507.44M as on Dec 31, 2025.
The company was founded in 2001 and is headquartered in Laguna Hills, United States, within the medical devices sector focused on ophthalmology. Operations center on the development of the Micro-Invasive Glaucoma Surgery (MIGS) method, including the iStent device, which is implanted during cataract surgery to reduce intraocular pressure. Additional platforms for bioerodible drug delivery targeting retinal disorders are also being advanced.
Glaukos's top competitors include Myra Vision, Ivantis and Transcend Medical.
Yes, Glaukos is publicly traded on NYSE under the ticker symbol GKOS.
Glaukos has made 1 acquisition, including Avedro.
Glaukos has 8 investors. Key investors include Orbimed, Frazier Healthcare Partners, Meritech Capital, Domain Associates, and InterWest.